Biogen beats quarterly estimates as newer drugs drive growth By Reuters
Biogen reported Q2 adjusted EPS of $3.60, above the $2.95 estimate, on revenue of $2.74 billion versus $2.46 billion expected, helped by rare-disease drugs. Rare-disease sales rose 11% to $602 million, while multiple-sclerosis drug sales fell 13% to $963 million. Biogen cut its 2026 adjusted EPS forecast to $12-$13 and expects full-year revenue growth in the mid-single digits.
How this was made
The 30-second read
Why it matters
The earnings beat and updated revenue outlook support a growth re-rating, but the lowered 2026 adjusted EPS forecast highlights near-term earnings drag from acquisition-related charges and ongoing MS portfolio decline.
Market read
Traders can reassess Biogen’s earnings power and growth trajectory using the specific Q2 print, the 2026 adjusted EPS guidance cut, and the full-year revenue growth expectation.
What to watch
Leqembi growth is described as tempered by cost, side effects, and efficacy concerns, so investors may scrutinize whether growth can re-accelerate without further pricing or uptake headwinds.
Background
Biogen is navigating a transition from older multiple sclerosis drugs toward newer rare-disease and Alzheimer’s assets, including Leqembi and products tied to its Apellis acquisition.
Ticker impact
Biogen beat Q2 profit and revenue estimates, raised rare-disease growth, and cut its 2026 adjusted EPS forecast due to acquisition-related charges.
Near-term upside bias from the earnings beat and rare-disease growth, with follow-through dependent on whether Leqembi and pipeline catalysts offset MS pricing pressure.
The article provides concrete Q2 results (EPS, revenue), a specific guidance cut for 2026 adjusted EPS, and directional full-year revenue growth expectations, all tied to Biogen’s product mix and pipeline.
Market effects
Signals continued resilience in rare-disease neurology franchises despite aging multiple sclerosis portfolio pressure.
None specific to Biogen beyond a broad mention of KOSPI performance.
Reinforces competitive and pricing pressure dynamics in Alzheimer’s and multiple sclerosis markets, with Leqembi growth still progressing.
Counterpoint
The guidance cut for 2026 adjusted EPS and the 13% year-over-year decline in multiple sclerosis sales may limit upside despite the rare-disease beat.
Key entities
- companyBiogen
Reported Q2 profit and revenue above estimates, rare-disease growth acceleration, and updated 2026 adjusted EPS and full-year revenue expectations.
- companyApellis Pharmaceuticals
Its $5.6 billion buyout earlier this year provided Biogen kidney-disease foothold and approved rare-disease drugs.
- companyEisai
Co-developer of Leqembi; Leqembi sales growth was cited in the article.
